The in-line quarter and reaffirmed guidance suggest limited near-term catalyst. Monitor Q3 results for medical segment traction and whether the non-recurring international orders create a sequential revenue dip. The VA/DoD distribution deal and Medicare reimbursement progress are longer-term positives but unlikely to drive immediate price action.
Price Chart
Executive Summary
Milestone Scientific reported Q2 2026 revenue of $2.8M (+22% YoY), in line with consensus, and EPS of -$0.01, matching estimates. The medical segment's CompuFlo revenue surged 230% YoY, and the company reaffirmed its 2026 outlook for double-digit revenue growth ($9.8M-$10.2M). However, gross margin contracted to 67.2% from 69.6% due to tariffs and mix, and the company noted that Q2 benefited from two large non-recurring international orders, with Q3 expected to be seasonally slower.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $2.84M, +22.3% YoY, in line with consensus of $2.7M
- EPS -$0.01, in line with consensus estimate of -$0.01
- Medical segment CompuFlo revenue grew 230% YoY
- Gross margin declined to 67.2% from 69.6% due to tariffs and product mix
- Operating expenses decreased 4.2% YoY to $3.0M
- Net loss narrowed to $1.1M from $1.5M YoY
- Cash and equivalents $2.1M, working capital $3.7M, convertible debt $466K
- Reaffirmed 2026 revenue guidance of $9.8M-$10.2M
- Q2 benefited from two large non-recurring international orders; Q3 expected seasonally slower
- Entered strategic distribution agreement with Red One Medical for VA/DoD channels
Financial Impact
Revenue in line with consensus; net loss narrowing; guidance maintained; no material surprise to move stock significantly
Risk Factors
- Q3 seasonally slower and non-recurring international orders may cause sequential revenue decline
- Gross margin pressure from tariffs and product mix could persist
- Cash burn continues; $2.1M cash may require additional financing before breakeven in early 2027
- Dependence on Medicare reimbursement expansion across remaining MAC jurisdictions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345258 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 28d ago | EFFECT | $0.4100 $0.3000 | ▲ +26.83% | ▲ +27.54% | $0.3000 (+26.83%) |
Sep 18, 2026 5w ago | S-3/A | $0.3908 $0.3330 | ▼ −14.79% | ▼ −13.88% | $0.3000 (−23.23%) |
Aug 14, 2026 10w ago | Press Release | $0.4951 $0.4240 | ▼ −14.36% | ▼ −12.37% | $0.3000 (−39.41%) |
Jul 31, 2026 12w ago | 8-K | $0.3990 | awaiting T+20 | — | $0.3000 (−24.81%) |
Jul 29, 2026 12w ago | 8-K | $0.3911 | awaiting T+20 | — | $0.3000 (−23.29%) |
Jun 10, 2026 19w ago | EFFECT | $0.3899 $0.3550 | ▲ +8.95% | ▲ +12.57% | $0.3000 (+23.06%) |
Jun 2, 2026 21w ago | S-3 | $0.3900 $0.3423 | ▲ +12.23% | ▲ +11.23% | $0.3000 (+23.08%) |
May 27, 2026 21w ago | Press Release | $0.3900 $0.3220 | ▼ −17.44% | ▼ −15.53% | $0.3000 (−23.08%) |
May 14, 2026 23w ago | Press Release | $0.3400 $0.3500 | ▲ +2.94% | ▲ +3.80% | $0.3000 (−11.76%) |
May 6, 2026 24w ago | 8-K | $0.4700 $0.3900 | ▼ −17.02% | ▼ −20.16% | $0.3000 (−36.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers